Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials

Objectives: This study systematically reviewed the published literature from clinical trials on the efficacy and immunogenicity of single-dose HPV vaccination compared to multidose schedules or no HPV vaccination. Methods: Four databases were searched for relevant articles published from Jan-1999 to...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Hilary S. Whitworth, Sandra Mounier-Jack, Edward M. Choi, Katherine E. Gallagher, Natasha Howard, Helen Kelly, Gladys Mbwanji, Aimée R Kreimer, Partha Basu, Ruanne Barnabas, Mélanie Drolet, Marc Brisson, Deborah Watson-Jones
Fformat:	Erthygl
Iaith:	English
Cyhoeddwyd:	Elsevier 2024-08-01
Cyfres:	Vaccine: X
Pynciau:	Human papillomavirus Vaccine Dosage Efficacy Immunogenicity
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2590136224000597

Eitemau Tebyg

Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China
gan: Mingzhu Li, et al.
Cyhoeddwyd: (2023-03-01)

The effect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males
gan: Rebecca F. Wu, et al.
Cyhoeddwyd: (2017-03-01)

Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals
gan: Xiao-Juan Yu, et al.
Cyhoeddwyd: (2020-07-01)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
gan: Suzanne M. Garland, et al.
Cyhoeddwyd: (2022-11-01)

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
gan: Vu Dinh Thiem, et al.
Cyhoeddwyd: (2021-07-01)

Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies
gan: Anna R. Giuliano, et al.
Cyhoeddwyd: (2025-12-01)

Human papillomavirus vaccine: An update on recent developments and review of real world data on efficacy
gan: Shalini Rajaram, et al.
Cyhoeddwyd: (2023-01-01)

A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine
gan: Dan Xu, et al.
Cyhoeddwyd: (2024-11-01)

The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20–45 years of age
gan: Tianmeng Wen, et al.
Cyhoeddwyd: (2024-12-01)

Modelling multi-site transmission of the human papillomavirus and its impact on vaccination effectiveness
gan: P. Lemieux-Mellouki, et al.
Cyhoeddwyd: (2017-12-01)

Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)
gan: Paulina N. Naupu, et al.
Cyhoeddwyd: (2020-12-01)

Immunogenicity and safety of the fourth dose of quadrivalent human papillomavirus (HPV) vaccine in immunosuppressed women who did not seroconvert after three doses
gan: Lívia Zignago Moreira dos Santos, et al.
Cyhoeddwyd: (2024-12-01)

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
gan: Sven-Eric Olsson, et al.
Cyhoeddwyd: (2020-12-01)

Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior
gan: Iacopo Baussano, et al.
Cyhoeddwyd: (2016-01-01)

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
gan: Katrina M. Nolan, et al.
Cyhoeddwyd: (2023-04-01)

Application of reverse cumulative distribution curve and scaled logit model in determining optimal immunogenic dose and prediction of protection of EV71 vaccines
gan: Lairun Jin, et al.
Cyhoeddwyd: (2025-12-01)

Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial
gan: Zhao-Jun Mo, et al.
Cyhoeddwyd: (2022-11-01)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
gan: Ivette Maldonado, et al.
Cyhoeddwyd: (2022-11-01)

Sleep and vaccine administration time as factors influencing vaccine immunogenicity
gan: Eun Seok Kim, et al.
Cyhoeddwyd: (2022-03-01)

In-silico Analysis of Human Papillomavirus – 45 E6, E7 & L1 Proteins as Potential Immunogens
gan: Shruthi Padavu, et al.
Cyhoeddwyd: (2023-03-01)

Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant
gan: Karina Takesaki Miyaji, et al.
Cyhoeddwyd: (2024-11-01)

Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countriesResearch in context
gan: Kiesha Prem, et al.
Cyhoeddwyd: (2024-08-01)

Discrepancies in the evaluation of the safety of the human papillomavirus vaccine
gan: Jorge L Cervantes, et al.
Cyhoeddwyd: (2018-05-01)

Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study
gan: Zhen-Zi Wang, et al.
Cyhoeddwyd: (2018-06-01)

Factors influencing the immunogenicity of influenza vaccines
gan: Simin Wen, et al.
Cyhoeddwyd: (2021-08-01)

Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial
gan: Ying-Ying Su, et al.
Cyhoeddwyd: (2020-07-01)

Human Papillomavirus Vaccine: A New Opportunity for The Treatment of Human Papillomavirus Infections
gan: Sneha Ambwani, et al.
Cyhoeddwyd: (2014-06-01)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
gan: Juan Li, et al.
Cyhoeddwyd: (2021-10-01)

Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
gan: Eva Hong, et al.
Cyhoeddwyd: (2017-03-01)

Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials
gan: Chantal Sauvageau, et al.
Cyhoeddwyd: (2020-03-01)

Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine
gan: Jiawei Xu, et al.
Cyhoeddwyd: (2024-05-01)

Resolution of Novel Human Papillomavirus–induced Warts after HPV Vaccination
gan: Steffi Silling, et al.
Cyhoeddwyd: (2014-01-01)

Influences of obesity on the immunogenicity of Hepatitis B vaccine
gan: Fang Liu, et al.
Cyhoeddwyd: (2017-05-01)

Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis
gan: Sara Carazo, et al.
Cyhoeddwyd: (2020-03-01)

Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review
gan: Mallory K. Ellingson, et al.
Cyhoeddwyd: (2023-08-01)

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
gan: Maria Zurek Munk-Madsen, et al.
Cyhoeddwyd: (2018-04-01)

Micronutrients to Support Vaccine Immunogenicity and Efficacy
gan: Philip C. Calder, et al.
Cyhoeddwyd: (2022-04-01)

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study
gan: Ingrid Herta Rotstein Grein, et al.
Cyhoeddwyd: (2020-11-01)

Immunogenicity of Alternative Dosing Schedules for HPV Vaccines among Adolescent Girls and Young Women: A Systematic Review and Meta-Analysis
gan: Andrew M. Secor, et al.
Cyhoeddwyd: (2020-10-01)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
gan: Rodrigo Luiz Carregaro, et al.
Cyhoeddwyd: (2023-08-01)